Immunovant, Inc. IMVT EPS (Basic)
EPS (Basic) at other companies
Other financials
Where this comes from
Reported directly by Immunovant, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareBasic.
The official record: Immunovant, Inc.’s 10-K, filed May 20, 2026, on SEC EDGAR. View the filing →
Ask your AI about Immunovant, Inc.'s eps (basic).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Immunovant, Inc.'s EPS (basic)?
- Immunovant, Inc. (IMVT) reported EPS (basic) of -$0.73 in Q1 2026.
- How has Immunovant, Inc.'s EPS (basic) changed year-over-year?
- Immunovant, Inc.'s EPS (basic) decreased by 15.9% year-over-year, from -$0.63 to -$0.73.
- What is the long-term trend for Immunovant, Inc.'s EPS (basic)?
- Over 4 years (2022 to 2026), Immunovant, Inc.'s EPS (basic) has grown at a 18.1% compound annual growth rate (CAGR), from -$1.43 to -$2.78.
- What does EPS (basic) mean?
- Net income available to common shareholders divided by the weighted-average number of common shares outstanding during the period. Does not account for dilutive securities.